Human Placenta-Derived Cells Pda001-
Middle Cerebral Artery Stroke
Celularity IncorporatedCell therapyPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Middle Cerebral Artery Stroke cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Recombinant Human Plasminogen Activator SOS Attaque Cérébrale | Phase 4 | BB |
Recombinant Human Erythropoietin Alfa Max-Planck-Institute of Experimental Medicine | Phase 2/3 | B |
PHYSIOLOGIC SODIUM CHLORIDE SOLUTION Max-Planck-Institute of Experimental Medicine | Phase 2/3 | B |
Auto-Cd34+ Cells Imperial College London | Phase 1/2 | CCC |
Piracetam UCB S.A. - Pharma Sector | Phase 4 | CCC |
View all 10 →
Same molecule, other indications
Human Placenta-Derived Cells Pda001- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →